Tags

Type your tag names separated by a space and hit enter

Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
J Med Econ. 2013 Sep; 16(9):1129-36.JM

Abstract

OBJECTIVE

The objective of this analysis was to compare costs of paricalcitol or cinacalcet plus low dose vitamin D, and of phosphate binders, in patients in the IMPACT SHPT study; and to extrapolate those to estimate expected annual maintenance costs.

METHODS

IMPACT SHPT was a 28-week, randomized, open-label trial. Subjects from 12 countries received intravenous (IV) or oral paricalcitol, or oral cinacalcet plus fixed IV doxercalciferol or oral alfacalcidol. The primary end-point was the proportion of subjects who achieved a mean intact parathyroid hormone (iPTH) value of 150-300 pg/mL during weeks 21-28 (evaluation period). This study compares the costs of study drugs and phosphate binders among participants during the study and annualized. This analysis includes only those subjects that reached the evaluation period (134 in each group).

RESULTS

The mean total drug costs over the study period were €2606 (SD = €2000) in the paricalcitol group and €3034 (SD = €3006) in the cinacalcet group (difference €428, p = 0.1712). The estimated annualized costs were €5387 (SD = €4139) in the paricalcitol group and €6870 (SD = €6256) in the cinacalcet group (difference €1492, p = 0.0395). In addition, a significantly greater proportion (p = 0.010) of subjects in the paricalcitol arm (56.0%) achieved an iPTH of 150-300 pg/mL during the evaluation period compared to the cinacalcet arm (38.2%).

LIMITATIONS

This was a secondary analysis of the IMPACT SHPT study which was not designed or powered for costs as an outcome. The dosing of study drugs and phosphate binders in the IMPACT study may not reflect actual practice, and patients were followed for 28 weeks, while the treatment of SHPT is long-term.

CONCLUSION

Patients with SHPT requiring hemodialysis who were treated with a paricalcitol-based regimen for iPTH control had lower estimated annual drug costs compared to those treated with cinacalcet plus low-dose vitamin D.

Authors+Show Affiliations

Nephrian, Thousand Oaks, CA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase IV
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23834479

Citation

Sharma, Amit, et al. "Comparative Cost Analysis of Management of Secondary Hyperparathyroidism With Paricalcitol or Cinacalcet With Low-dose Vitamin D in Hemodialysis Patients." Journal of Medical Economics, vol. 16, no. 9, 2013, pp. 1129-36.
Sharma A, Ketteler M, Marshall TS, et al. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. J Med Econ. 2013;16(9):1129-36.
Sharma, A., Ketteler, M., Marshall, T. S., Khan, S. S., & Schumock, G. T. (2013). Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. Journal of Medical Economics, 16(9), 1129-36. https://doi.org/10.3111/13696998.2013.823092
Sharma A, et al. Comparative Cost Analysis of Management of Secondary Hyperparathyroidism With Paricalcitol or Cinacalcet With Low-dose Vitamin D in Hemodialysis Patients. J Med Econ. 2013;16(9):1129-36. PubMed PMID: 23834479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. AU - Sharma,Amit, AU - Ketteler,Markus, AU - Marshall,Thomas S, AU - Khan,Samina S, AU - Schumock,Glen T, Y1 - 2013/07/24/ PY - 2013/7/10/entrez PY - 2013/7/10/pubmed PY - 2014/4/8/medline SP - 1129 EP - 36 JF - Journal of medical economics JO - J Med Econ VL - 16 IS - 9 N2 - OBJECTIVE: The objective of this analysis was to compare costs of paricalcitol or cinacalcet plus low dose vitamin D, and of phosphate binders, in patients in the IMPACT SHPT study; and to extrapolate those to estimate expected annual maintenance costs. METHODS: IMPACT SHPT was a 28-week, randomized, open-label trial. Subjects from 12 countries received intravenous (IV) or oral paricalcitol, or oral cinacalcet plus fixed IV doxercalciferol or oral alfacalcidol. The primary end-point was the proportion of subjects who achieved a mean intact parathyroid hormone (iPTH) value of 150-300 pg/mL during weeks 21-28 (evaluation period). This study compares the costs of study drugs and phosphate binders among participants during the study and annualized. This analysis includes only those subjects that reached the evaluation period (134 in each group). RESULTS: The mean total drug costs over the study period were €2606 (SD = €2000) in the paricalcitol group and €3034 (SD = €3006) in the cinacalcet group (difference €428, p = 0.1712). The estimated annualized costs were €5387 (SD = €4139) in the paricalcitol group and €6870 (SD = €6256) in the cinacalcet group (difference €1492, p = 0.0395). In addition, a significantly greater proportion (p = 0.010) of subjects in the paricalcitol arm (56.0%) achieved an iPTH of 150-300 pg/mL during the evaluation period compared to the cinacalcet arm (38.2%). LIMITATIONS: This was a secondary analysis of the IMPACT SHPT study which was not designed or powered for costs as an outcome. The dosing of study drugs and phosphate binders in the IMPACT study may not reflect actual practice, and patients were followed for 28 weeks, while the treatment of SHPT is long-term. CONCLUSION: Patients with SHPT requiring hemodialysis who were treated with a paricalcitol-based regimen for iPTH control had lower estimated annual drug costs compared to those treated with cinacalcet plus low-dose vitamin D. SN - 1941-837X UR - https://www.unboundmedicine.com/medline/citation/23834479/Comparative_cost_analysis_of_management_of_secondary_hyperparathyroidism_with_paricalcitol_or_cinacalcet_with_low_dose_vitamin_D_in_hemodialysis_patients_ L2 - https://www.tandfonline.com/doi/full/10.3111/13696998.2013.823092 DB - PRIME DP - Unbound Medicine ER -